You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The total investment comes to more than $283 million for a program focused on COVID-19 testing of people disproportionately affected by the pandemic, the NIH said.
The test is designed to detect and visualize abnormal phosphorylated alpha-synuclein — a hallmark of synucleinopathies — in cutaneous nerve fibers.
The test, which is licensed to rHealth, monitors FVIII levels in the blood of patients with hemophilia A patients, who lack the clotting protein.
More than 25 academic, government, and private research institutions will be part of the network, which aims to speed up delivery of testing, therapies, and vaccines.
The money will be used to understand COVID-19 testing patterns in vulnerable populations and develop strategies to reduce testing disparities.
Some of the firms will receive money to speed up test development, while others will use the funds to expand their testing and manufacturing capacity.
The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.
In December the firm won $4 million from CARB-X to support the platform's first test identifying the most common bloodstream infections associated with sepsis.
The total relief package totals $484 billion, including $11 billion for states, localities, territories, tribes, and employers to scale up SARS-CoV-2 testing.
The Bill & Melinda Gates Foundation will also provide support to winners of the challenge, which may include a grant of up to $500,000.